Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury

Thrombosis and Haemostasis

Volumn 81, Issue 4, 1999, Pages 601-604

  Matsuno, Hiroyuki ^a,b,d   Kozawa, Osamu ^a   Niwa, Masayuki ^a   Ueshima, Shigeru ^b   Matsuo, Osamu ^b   Collen, Désiré ^c   Uematsu, Toshihiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSE BENGAL; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW; BLOOD VESSEL OCCLUSION; CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM INJURY; FIBRINOLYSIS; LIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 0032899058     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614532     Document Type: Article

References (30)

1. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46.
2. Matsuo O. Rijken DC, Collen D. Thromholvsis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary erabo-lus. Nature 1981; 291: 590-1.
3. Matsuo O, Banjo H, Okada K. Tanaka K. Sucked M. Ida Y. Armour H. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model. Thromh Res 1986:42: 187-94.
4. Collen D. Lijnen HR. Basic and clinical aspects of fihrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
5. Plow EF, Herren T. Redlilz A. Miles LA. Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-45.
6. 2-antiplasmin on plasminogen activation by staphylokinase. Am J Hematol 1996: 53: 151-7.
7. Levi M. Biemond BJ. van Zonneveld AJ. ten Gate JW. Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992: 85: 305-12.
8. Braaten JV, Handt S. Jerome WG. Kirkpatrick J. Lewis JC. Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhib-itor I : light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993: 81: 1290-9.
9. Stringer HA. van Swieten P, Heijnen HF. Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-8.
10. Kunitada S, FitzGerald GA. Fitzgerald DJ. Inhibition of clot lysis and de-creased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992: 79: 1420-7.
11. Matsuno H. Uematsu T. Nagashima S. Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Meth 1991; 25: 303-17.
12. Matsuno H. Uematsu T. Umemura K, Takiguchi Y. Wada K. Nakashima M. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br J Pharmacol 1992; 106: 533-8.
13. Hirata Y. Takiguchi Y, Wada K, Matsuno H. Umemura K. Uematsu T, Nakashima M. Roles of platelet-activating factor, thromboxane A2. ADP and thrombin in thrombogenesis in the guinea pig. Eur J Pharmacol 1993; 231:421-5.
14. Takiguchi Y. Shimazawa M, Nakashim M. A comparative study of the anti-thrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs. Br J Pharmacol 1996; 118: 1633-8.
15. Carmeliet P. Kieckens L. Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M. Bronson R. Collen D. Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-55.
16. Carmeliet P, Schoonjans L. Kieckens L, Ream B, Degen J. Bronson R, De Vos R. van den Oord JJ. Collen D, Mulligan RC. Physiological consequence of loss of plasminogen activator gene function in mice. Nature 1994: 368: 419-24.
17. Carmeliet P. Stassen JM. Schoonjans L. Ream B. van den Oord JJ, De Mol M. Mulligan RC. Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis. thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
18. Carmeliet P. Stassen JM, Van Vlaenderen I. Meidell RS. Collen D. Gerard RD. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 1997; 90: 1527-34.
19. Ploplis VA, Carmeliet P. Vazirzadeh S, Van Vlaenderen I. Moons L. Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-93.
20. Matsuno H, Kozawa O. Niwa M. Kaida T, Hayashi H. Uematsu T. GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan. an angiotensin 11 receptor antagonist, in the injured carotid artery of hamster. Br J Pharmacol 1997; 122: 1099-104.
21. DeWood MA, Spores J, Notske R. Mouser LT. Burroughs R. Golden MS. Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
22. Boehrer JD, Glamann DB, Lange RA. Willard JE, Brogan WC 3rd. Eichhorn EJ, Grayburn PA. Anwar A, Hillis LD. Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction. Am J Cardiol 1992; 70: 1515-9.
23. Simes RJ, Topol EJ, Holmes DR Jr. White HD. Rutsch WR, Vahanian A, Simoons ML. Morris D, Betriu A, Califf RM, et al. Link between the angio-graphie substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-1 Investigators. Circulation 1995; 91: 1923-8.
24. Strickland S. Reich E. Sherman MI. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 1976; 9: 231-40.
25. Rifkin DB, Moscatelli D. Bizik J. Quarto N. Blei F. Dennis P. Flaumenhaft R, Mignatti P. Growth factor control of extracellular proteolysis. Cell Diff Devel 1990; 32: 313-8.
26. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 1990; 82: 1485-93.
27. Reilly CF, Fujita T. Mayer EJ, Siegfried ME. Both circulating and clotbound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscl Thromb 1991; 11: 1276-86.
28. Marsh JJ, Konopka RG, Lang IM, Wang HY. Pedersen C. Chiles P, Reilly CF, Moser KM. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation 1994: 90: 3091-7.
29. Dieval J, Nguyen G, Gross S. Delobel J. Kruithof EK. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-32.
30. Lee MH. Vosburgh E, Anderson K. McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-62.